Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at https://aems.tga.gov.au/

Adverse events can also be reported to Mundipharma at Drugsafety@mundipharma.com.au

Mundipharma Logo
CAPTCHA
Anti-Robot Verification
FriendlyCaptcha ⇗
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

* Required Fields

Report Adverse Event

Adverse events should be reported. Reporting forms and information can be found at https://aems.tga.gov.au/

Adverse events can also be reported to Mundipharma at Drugsafety@mundipharma.com.au

Skip to main content

MundiPharma-Logo
Report adverse event Login Register
country country AU
  • A
  • Australia Australia (AU)
  • B
  • Brazil Brazil (BR)
  • F
  • France France (FR)
  • G
  • Germany Germany (DE)
  • I
  • Italy Italy (IT)
  • J
  • Japan Japan (JP)
  • S
  • Spain Spain (ES)
  • U
  • United Kingdom United Kingdom (UK)
  • Therapy Areas
    • Central Precocious Puberty (CPP)
    • Prostate Cancer (PCA)
    • Peripheral T-cell Lymphoma (PTCL)
  • Medicines
    • ELIGARD®  FOR CPP
    • ELIGARD®  for PCA
    • FOLOTYN® 
  • Resources
    • Webinar & Videos
    • Other Resources
  • About Us
Report adverse event
Login Register
country country AU
  • A
  • Australia Australia (AU)
  • B
  • Brazil Brazil (BR)
  • F
  • France France (FR)
  • G
  • Germany Germany (DE)
  • I
  • Italy Italy (IT)
  • J
  • Japan Japan (JP)
  • S
  • Spain Spain (ES)
  • U
  • United Kingdom United Kingdom (UK)
Subscribe to Norspan
Napp Logo - A member of the Mundipharma network of associated companies
country country AU
  • A
  • Australia Australia (AU)
  • B
  • Brazil Brazil (BR)
  • F
  • France France (FR)
  • G
  • Germany Germany (DE)
  • I
  • Italy Italy (IT)
  • J
  • Japan Japan (JP)
  • S
  • Spain Spain (ES)
  • U
  • United Kingdom United Kingdom (UK)
Site Directory
  • Therapy Areas
    • Central Precocious Puberty (CPP)
    • Prostate Cancer (PCA)
    • Peripheral T-cell Lymphoma (PTCL)
  • Medicines
    • ELIGARD® FOR CPP
    • ELIGARD® for PCA
    • FOLOTYN®
  • Resources
    • Webinar & Videos
    • Other Resources
  • About Us
  • CONTACT US
  • LEGAL
  • COOKIE POLICY
  • PRIVACY
  • Therapy Areas
    • Central Precocious Puberty (CPP)
    • Prostate Cancer (PCA)
    • Peripheral T-cell Lymphoma (PTCL)
  • Medicines
    • ELIGARD® FOR CPP
    • ELIGARD® for PCA
    • FOLOTYN®
  • Resources
    • Webinar & Videos
    • Other Resources
  • About Us

Copyright Mundipharma Pharmaceuticals. All Rights Reserved. | JOB CODE: AU-NPR-2200022 | Prepared: April 2022

STAY CONNECTED

Opioid Charter

Opioid Charter For Mundipharma's Charter on the responsible medical use of opioid analgesics in pain management Click Here..

Opioid Safety Statement

"Attention should be given as the use of opioids has a risk of addiction, misuse and abuse. Therefore, appropriate assessment and monitoring is required at initiation, maintenance and tapering down of opioid therapy."

Others
NA